Sign in

    Justin Zelen

    Director and Senior Biotechnology Analyst at BTIG

    Justin Zelin is a Director and Senior Biotechnology Analyst at BTIG, specializing in research on cell therapy, targeted oncology, immunology, and auto-immune disease therapeutics. He has provided coverage for companies including Viking Therapeutics, 89bio, Syndax Pharmaceuticals, Kura Oncology, Poseida Therapeutics, and ProKidney, and has published detailed investment recommendations for these firms, with his stock picks tracked by platforms like MarketBeat. Zelin began his equity research career after roles in academic and industry labs at organizations such as Agenus, Harvard University, and Brigham and Women’s Hospital, subsequently holding research analyst and associate positions at B. Riley Securities, Canaccord Genuity, and SVB Leerink before joining BTIG in January 2021. He holds both a master’s degree in biotechnology and a bachelor’s degree in biology from Harvard University, and leverages his formal scientific training and teaching experience at Harvard in his analytical approach.

    Justin Zelen's questions to Lite Strategy (MEIP) leadership

    Justin Zelen's questions to Lite Strategy (MEIP) leadership • Q4 2021

    Question

    Justin Zelen of BTIG asked about the broader development plan and the expected cadence of data releases for expanding zandelisib into other indications following the initial monotherapy data in follicular lymphoma.

    Answer

    Dan Gold, President and CEO, outlined a strategy focused on establishing zandelisib as a backbone therapy through various combinations. He highlighted ongoing and planned studies combining zandelisib with zanubrutinib, rituximab, and venetoclax across follicular lymphoma, mantle cell lymphoma, and CLL. The goal is to provide effective, non-chemotherapy combination regimens in earlier lines of therapy and additional indications.

    Ask Fintool Equity Research AI